Gilead Sciences (GILD) came out with quarterly earnings of $2.47 per share, beating the Zacks Consensus Estimate of $2.15 per share. This compares to earnings of $2.02 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +14.88%. A quarter ago, it was expected that this HIV and hepatitis C drugmaker would post earnings of $1.95 per share when it actually produced earnings of $2.01, delivering a surprise of +3.08%.Over the last four ...

Company Performance - Gilead Sciences (GILD) closed at $121.46, reflecting a -2.11% change from the previous day, underperforming the S&P 500's loss of 0.53% [1] - Prior to this trading session, Gilead's shares had increased by 8.46%, outperforming the Medical sector's gain of 3.64% and the S&P 500's gain of 1.13% [1] Upcoming Earnings - Gilead Sciences is set to disclose its earnings on October 30, 2025, with an anticipated EPS of $2.15, representing a 6.44% increase from the same quarter last year [2] - The consensus estimate for quarterly revenue is $7.46 billion, which is a decrease of 1.14% compared to the previous year [2] Fiscal Year Estimates - For the entire fiscal year, Zacks Consensus Estimates predict earnings of $8.07 per share and revenue of $28.78 billion, indicating increases of +74.68% and +0.08% respectively from the prior year [3] - Recent changes to analyst estimates for Gilead Sciences reflect near-term business trends, with positive revisions indicating analysts' confidence in the company's performance [3][4] Valuation Metrics - Gilead Sciences has a Forward P/E ratio of 15.38, which is lower than the industry average Forward P/E of 20.42, suggesting a valuation discount [6] - The company also has a PEG ratio of 0.85, compared to the industry average PEG ratio of 1.67, indicating favorable growth expectations relative to its valuation [7] Industry Context - The Medical - Biomedical and Genetics industry, which includes Gilead, has a Zacks Industry Rank of 92, placing it in the top 38% of over 250 industries [8] - Strong industry rankings correlate with performance, as the top 50% of rated industries tend to outperform the bottom half by a factor of 2 to 1 [8]

Core Insights - Gilead Sciences (GILD) stock closed at $112.69, reflecting a +1.93% change from the previous day, outperforming the S&P 500's gain of 0.01% [1] - The stock has decreased by 1.96% over the past month, underperforming the Medical sector's increase of 4.67% and the S&P 500's rise of 4.83% [1] Earnings Performance - Gilead Sciences is expected to report an EPS of $2.15, representing a 6.44% increase from the same quarter last year [2] - Revenue is forecasted at $7.43 billion, indicating a 1.59% decline compared to the same quarter last year [2] Annual Estimates - For the annual period, earnings are anticipated to be $8.08 per share, with revenue projected at $28.75 billion, reflecting increases of +74.89% and no change, respectively, from the previous year [3] Analyst Sentiment - Recent changes in analyst estimates suggest optimism regarding Gilead Sciences' business and profitability [3] - The Zacks Consensus EPS estimate has decreased by 0.21% over the last 30 days, and Gilead Sciences currently holds a Zacks Rank of 3 (Hold) [5] Valuation Metrics - Gilead Sciences has a Forward P/E ratio of 13.68, which is lower than the industry average of 19.42, indicating it is trading at a discount [6] - The PEG ratio for Gilead Sciences is currently 0.75, compared to the industry average of 1.82, suggesting favorable valuation relative to growth expectations [7] Industry Context - The Medical - Biomedical and Genetics industry, where Gilead operates, has a Zacks Industry Rank of 74, placing it in the top 30% of over 250 industries [7] - Research indicates that top-rated industries outperform lower-rated ones by a factor of 2 to 1 [8]

Company Performance - Gilead Sciences (GILD) closed at $110.99, reflecting a -2.36% change from the previous day, underperforming the S&P 500's daily loss of 0.5% [1] - Over the past month, Gilead's shares have decreased by 0.22%, outperforming the Medical sector's loss of 0.7% but lagging behind the S&P 500's gain of 2.74% [1] Upcoming Earnings - Analysts expect Gilead to report an EPS of $2.15, a 6.44% increase compared to the same quarter last year, with a projected quarterly revenue of $7.43 billion, down 1.59% from the previous year [2] - For the annual period, earnings are anticipated to be $8.08 per share and revenue at $28.75 billion, indicating a +74.89% change in earnings and no change in revenue from last year [3] Analyst Revisions and Rankings - Recent revisions to analyst forecasts are crucial as they reflect near-term business trends, with positive revisions indicating confidence in Gilead's performance [3] - Gilead currently holds a Zacks Rank of 3 (Hold), with the Zacks Consensus EPS estimate having decreased by 0.22% over the last 30 days [5] Valuation Metrics - Gilead Sciences has a Forward P/E ratio of 14.06, which is lower than the industry average of 19.43, suggesting it is trading at a discount [6] - The company has a PEG ratio of 0.77, compared to the industry average of 1.72, indicating a favorable valuation relative to expected earnings growth [7] Industry Context - The Medical - Biomedical and Genetics industry, which includes Gilead, has a Zacks Industry Rank of 88, placing it in the top 36% of over 250 industries [8]

Core Insights - Gilead Sciences reported quarterly earnings of $2.01 per share, exceeding the Zacks Consensus Estimate of $1.95 per share, with an earnings surprise of +3.08% [1] - The company generated revenues of $7.08 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.95% and showing a year-over-year increase from $6.95 billion [2] - Gilead's stock has increased by approximately 19.4% year-to-date, outperforming the S&P 500's gain of 7.9% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $2.16, with expected revenues of $7.45 billion, and for the current fiscal year, the EPS estimate is $8.02 on revenues of $28.68 billion [7] - The estimate revisions trend for Gilead was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Gilead belongs, is currently ranked in the top 41% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Company Performance - Gilead Sciences (GILD) closed at $109.06, reflecting a -2.7% change from the previous day, underperforming the S&P 500's daily loss of 0.4% [1] - Over the past month, Gilead's shares gained 1.14%, while the Medical sector lost 1.56% and the S&P 500 gained 4.97% [1] Earnings Projections - The upcoming EPS for Gilead is projected at $2, indicating a 0.50% decline compared to the same quarter last year, with anticipated revenue of $7.03 billion, a 1.07% increase from the same quarter last year [2] - For the full year, analysts expect earnings of $7.94 per share and revenue of $28.68 billion, representing changes of +71.86% and -0.24% respectively from the previous year [3] Analyst Estimates and Rankings - Recent changes in analyst estimates for Gilead are crucial as they reflect near-term business trends, with positive revisions indicating analysts' confidence in the company's performance [4] - The Zacks Rank system, which incorporates estimate changes, currently ranks Gilead as 2 (Buy), with a consensus EPS projection moving 0.29% higher in the past 30 days [6] Valuation Metrics - Gilead Sciences is trading at a Forward P/E ratio of 14.12, which is below the industry average of 17.7, indicating a discount compared to its peers [7] - The company has a PEG ratio of 0.72, significantly lower than the industry average PEG ratio of 1.5, suggesting favorable valuation relative to expected earnings growth [8] Industry Context - The Medical - Biomedical and Genetics industry, which includes Gilead, holds a Zacks Industry Rank of 77, placing it in the top 32% of over 250 industries [9]

Core Viewpoint - Gilead Sciences has experienced a decline in stock performance recently, and various factors, including earnings estimates and revenue growth, will influence its future stock trajectory [2][5][11]. Earnings Estimate Revisions - Gilead is projected to report earnings of $1.99 per share for the current quarter, reflecting a year-over-year decrease of 1% [5]. - The consensus earnings estimate for the current fiscal year is $7.91, indicating a significant year-over-year increase of 71.2% [5]. - For the next fiscal year, the consensus estimate is $8.39, representing a year-over-year growth of 6.1% [6]. - The Zacks Rank for Gilead is 3 (Hold), indicating a neutral outlook based on recent earnings estimate revisions [7]. Revenue Growth Forecast - The consensus sales estimate for Gilead in the current quarter is $7 billion, showing a year-over-year increase of 0.6% [11]. - Revenue estimates for the current and next fiscal years are $28.51 billion (a decrease of 0.8%) and $29.78 billion (an increase of 4.5%), respectively [11]. Last Reported Results and Surprise History - Gilead reported revenues of $6.67 billion in the last quarter, which is a year-over-year decline of 0.3% [12]. - The EPS for the last reported quarter was $1.81, compared to -$1.32 a year ago, with a revenue surprise of -2.46% and an EPS surprise of -0.55% [12]. - Over the last four quarters, Gilead has surpassed consensus EPS estimates three times and revenue estimates three times [13]. Valuation - Gilead's valuation metrics, including price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), are essential for assessing whether the stock is fairly valued [14][15]. - The Zacks Value Style Score for Gilead is graded B, indicating that the stock is trading at a discount compared to its peers [17].

Core Viewpoint - Gilead Sciences reported quarterly earnings of $1.81 per share, slightly missing the Zacks Consensus Estimate of $1.82 per share, but showing improvement from a loss of $1.32 per share a year ago [1][2] Financial Performance - The company posted revenues of $6.67 billion for the quarter ended March 2025, which was 2.46% below the Zacks Consensus Estimate and a slight decrease from $6.69 billion in the same quarter last year [2] - Over the last four quarters, Gilead has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Performance - Gilead shares have increased by approximately 15.2% since the beginning of the year, contrasting with the S&P 500's decline of 8.6% [3] - The stock currently holds a Zacks Rank of 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $2.01 on revenues of $6.98 billion, while for the current fiscal year, the estimate is $7.92 on revenues of $28.71 billion [7] - The outlook for the Medical - Biomedical and Genetics industry is positive, ranking in the top 32% of over 250 Zacks industries, suggesting potential for outperformance [8]

Core Viewpoint - Gilead Sciences is showing resilience in its stock performance compared to broader market indices, with upcoming earnings expected to demonstrate significant growth in EPS and stable revenue growth [1][2]. Company Performance - Gilead Sciences' stock closed at $112.39, reflecting a +0.45% change, outperforming the S&P 500, which fell by 4.84% [1]. - Over the past month, Gilead's shares have decreased by 3.08%, better than the Medical sector's decline of 4.6% and the S&P 500's drop of 4.7% [1]. Earnings Forecast - The company is set to release its earnings report on April 24, 2025, with an expected EPS of $1.73, indicating a 231.06% increase from the same quarter last year [2]. - Revenue is projected at $6.8 billion, reflecting a 1.67% increase year-over-year [2]. Annual Estimates - For the annual period, earnings are anticipated to be $7.87 per share, representing a +70.35% change, while revenue is expected to be $28.56 billion, showing a slight decrease of -0.67% from the previous year [3]. Analyst Sentiment - Recent adjustments to analyst estimates for Gilead Sciences indicate positive sentiment regarding the company's business operations and profit generation capabilities [4]. - The Zacks Rank system currently rates Gilead Sciences as 2 (Buy), suggesting favorable analyst outlook [6]. Valuation Metrics - Gilead Sciences has a Forward P/E ratio of 14.22, which is lower than the industry average of 17.83, indicating a potential undervaluation [7]. - The company also has a PEG ratio of 0.73, compared to the industry average of 1.43, suggesting that Gilead's stock may be undervalued relative to its expected earnings growth [7]. Industry Context - The Medical - Biomedical and Genetics industry, to which Gilead belongs, ranks in the top 31% of all industries, indicating strong performance relative to peers [8].

Core Viewpoint - Gilead Sciences is set to report its financial results on April 24, 2025, with significant expected growth in earnings per share (EPS) and revenue compared to the previous year [2][3]. Financial Performance - Gilead Sciences' stock closed at $111.88, reflecting a +0.54% change from the previous day, underperforming the S&P 500's gain of 0.67% [1] - The company is forecasted to report an EPS of $1.73, representing a 231.06% increase year-over-year [2] - Revenue is anticipated to be $6.8 billion, indicating a 1.67% increase from the same quarter last year [2] - Full-year estimates project earnings of $7.87 per share and revenue of $28.56 billion, showing year-over-year changes of +70.35% and -0.67%, respectively [3] Analyst Projections - Recent shifts in analyst projections for Gilead Sciences are important indicators of changing business trends, with positive revisions suggesting a favorable outlook [4] - The Zacks Consensus EPS estimate has increased by 0.16% over the last 30 days, and Gilead Sciences currently holds a Zacks Rank of 2 (Buy) [6] Valuation Metrics - Gilead Sciences has a Forward P/E ratio of 14.14, which is lower than the industry average of 17.2, indicating a potential undervaluation [7] - The company has a PEG ratio of 0.73, compared to the industry average of 1.41, suggesting that Gilead may be undervalued relative to its expected earnings growth [7] Industry Context - The Medical - Biomedical and Genetics industry, which includes Gilead Sciences, has a Zacks Industry Rank of 72, placing it in the top 29% of over 250 industries [8] - Strong industry rankings correlate with better stock performance, with the top 50% rated industries outperforming the bottom half by a factor of 2 to 1 [8]